Less aggressive approaches in relapsed/refractory Hodgkin lymphoma

Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, highlights areas of unmet need for patients with relapsed/refractory Hodgkin lymphoma (HL), including personalized, less aggressive approaches in the second-line setting, and potentially removing transplantation from the treatment approach for favorable patients with Hodgkin lymphoma. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.